NAT COMMUN:病例研究显示,APOE2降低阿尔兹海默症发病几率

2020-04-21 MedSci原创 MedSci原创

已有的研究显示,脂蛋白E4(APOE4)等位基因每增加一个拷贝,都与阿尔茨海默氏痴呆的风险增高有关,而APOE2等位基因与阿尔茨海默氏痴呆的风险较低有关。

已有的研究显示,脂蛋白E4(APOE4)等位基因每增加一个拷贝,都与阿尔茨海默氏痴呆的风险增高有关,而APOE2等位基因与阿尔茨海默氏痴呆的风险较低有关。但至今为止,我们尚不清楚APOE2纯合子遗传体是否具有特别低的风险。

因此,最近研究人员在5000多例具有临床特征和神经病理学特征的阿尔茨海默痴呆病例和对照组中进行了阿尔茨海默氏痴呆的几率比和其他方面的研究。

与APOE2/3和3/3相比,APOE2/2基因型发生阿尔茨海默氏痴呆的几率比较低。与APOE4/4相比,APOE2/2基因型发生阿尔茨海默氏痴呆的几率尤其低。在神经病理证实的组中,APOE2和APOE4基因剂量的影响明显大于24000多例神经病理未证实的病例和对照组。

找到并靶向APOE及其变异体影响阿尔茨海默病的因素,可能对理解、治疗和预防阿尔茨海默病产生重大影响。

 

原始出处:

Reiman EM et al. Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. NATURE COMMUNICATIONS, 2020. doi: 10.1038/s41467-019-14279-8.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2016403, encodeId=227a2016403e5, content=<a href='/topic/show?id=0fa1e0783cb' target=_blank style='color:#2F92EE;'>#病例研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70783, encryptionId=0fa1e0783cb, topicName=病例研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Feb 07 10:46:16 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087680, encodeId=f94b208e68001, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jun 07 05:46:16 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884266, encodeId=a4af1884266c1, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 12 12:46:16 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402792, encodeId=97d51402e9282, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Thu Apr 23 00:46:16 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590602, encodeId=f793159060204, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Thu Apr 23 00:46:16 CST 2020, time=2020-04-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2016403, encodeId=227a2016403e5, content=<a href='/topic/show?id=0fa1e0783cb' target=_blank style='color:#2F92EE;'>#病例研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70783, encryptionId=0fa1e0783cb, topicName=病例研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Feb 07 10:46:16 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087680, encodeId=f94b208e68001, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jun 07 05:46:16 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884266, encodeId=a4af1884266c1, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 12 12:46:16 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402792, encodeId=97d51402e9282, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Thu Apr 23 00:46:16 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590602, encodeId=f793159060204, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Thu Apr 23 00:46:16 CST 2020, time=2020-04-23, status=1, ipAttribution=)]
    2020-06-07 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=2016403, encodeId=227a2016403e5, content=<a href='/topic/show?id=0fa1e0783cb' target=_blank style='color:#2F92EE;'>#病例研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70783, encryptionId=0fa1e0783cb, topicName=病例研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Feb 07 10:46:16 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087680, encodeId=f94b208e68001, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jun 07 05:46:16 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884266, encodeId=a4af1884266c1, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 12 12:46:16 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402792, encodeId=97d51402e9282, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Thu Apr 23 00:46:16 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590602, encodeId=f793159060204, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Thu Apr 23 00:46:16 CST 2020, time=2020-04-23, status=1, ipAttribution=)]
    2021-01-12 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=2016403, encodeId=227a2016403e5, content=<a href='/topic/show?id=0fa1e0783cb' target=_blank style='color:#2F92EE;'>#病例研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70783, encryptionId=0fa1e0783cb, topicName=病例研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Feb 07 10:46:16 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087680, encodeId=f94b208e68001, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jun 07 05:46:16 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884266, encodeId=a4af1884266c1, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 12 12:46:16 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402792, encodeId=97d51402e9282, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Thu Apr 23 00:46:16 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590602, encodeId=f793159060204, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Thu Apr 23 00:46:16 CST 2020, time=2020-04-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2016403, encodeId=227a2016403e5, content=<a href='/topic/show?id=0fa1e0783cb' target=_blank style='color:#2F92EE;'>#病例研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70783, encryptionId=0fa1e0783cb, topicName=病例研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Feb 07 10:46:16 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087680, encodeId=f94b208e68001, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jun 07 05:46:16 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884266, encodeId=a4af1884266c1, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 12 12:46:16 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402792, encodeId=97d51402e9282, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Thu Apr 23 00:46:16 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590602, encodeId=f793159060204, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Thu Apr 23 00:46:16 CST 2020, time=2020-04-23, status=1, ipAttribution=)]
    2020-04-23 xiongke016

相关资讯

突破!阻断癌症和阿尔兹海默氏症的新一代药物或将问世

来自沃威克大学的研究人员近日通过研究开发出了抑制癌症和阿尔兹海默氏症的新一代药物。研究者Ioannis Nezis领导的研究团队鉴别并且创建了一个数据库,数据库中包含有自体吞噬作用(自噬)所需的多种蛋白质,而自体吞噬作用可以帮助维持机体健康,但随着年龄增长,这种作用的功能就会下降。 深入理解这些蛋白质的工作机制或可帮助开发新型药物来阻断自噬作用功能的下降,同时还可以长久地维持细胞健康,并且抑制主

Sci Rep:世界上阿尔兹海默氏症疫苗的研究进展

每年都有750多万阿尔兹海默氏症新发病例,因此寻找新型疫苗及痴呆症的有效疗法显得迫在眉睫。近日,一项刊登于国际杂志Scientific Reports上的研究报告中,来自美国和澳大利亚的研究人员通过研究发现了一种新型潜在的疫苗,该疫苗可以靶向作用和阿尔兹海默氏症疾病相关的病理性蛋白,阿尔兹海默氏症是引发老年人痴呆的常见原因。文章中,研究者成功开发了一种疫苗组分,其可以靶向作用异常的β淀粉样蛋白和t

我们距离血液测试来诊断阿尔兹海默氏症之路到底还有多远?

任何曾经拜访过医生的个体都非常熟悉利用血液检测来诊断多种疾病,由于血液同机体所有的器官都相互接触,因此其携带着指示这些器官健康与否的标志物;血液是一种方便获取的体液,其可以用来追踪患者机体疾病的进展情况,在很多情况下,血液检测往往相对便宜一些。因此利用血液来对痴呆症,尤其是阿尔兹海默氏症进行检测或许并不是一件奇怪的事情,而且其往往还得到了公众的关注。最近,进行阿尔兹海默氏症的诊断测试取得了突破

JAD:阿尔兹海默氏症血液检测获重大突破

近日,一项刊登在Journal of Alzheimer's Disease杂志上的研究报告中,来自卡迪夫大学等机构的研究者通过研究在开发诊断初期阿尔兹海默氏症的血液检测技术上取得了突破性的进展。该项研究由阿尔兹海默氏症协会提供资助。 文章中,研究人员对292名有早期记忆缺失迹象的个体的血液标本进行了研究,结果发现了一系列预测疾病的生物标志物,这些标志物或可帮助预测特定个体患阿尔兹海默氏症的风险

NATURE:阿尔兹海默症中tau蛋白主要通过LRP1传播

最近,研究人员的实验结果表明,低密度脂蛋白受体相关蛋白1(LRP1)控制了tau的内吞作用及其随后的传播。

FAN:首次发现益生菌或可改善阿尔兹海默氏症患者大脑的认知功能!

图片摘自:decidedlynutritious.com 日前,一项刊登在国际杂志Frontiers in Aging Neuroscience上的研究报告中,来自伊斯兰阿萨德大学等机构的研究人员通过研究首次发现,益生菌能够改善人类大脑的认知功能,在最新的临床试验中,科学家们通过研究发现,在为期12周的研究中,每日单一剂量的乳酸菌和双歧杆菌或许能够明显改善在细微精神状态检查(MMSE)老年阿